Tofogliflozin
- Generic Name
- Tofogliflozin
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26O6
- CAS Number
- 903565-83-3
- Unique Ingredient Identifier
- 554245W62T
- Background
Tofogliflozin has been used in trials studying the treatment and prevention of Diabetes Mellitus Type 2.
Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER and CSG452
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05722262
- Locations
- 🇺🇸
PPD - Austin Research Unit, Austin, Texas, United States
Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)
- Conditions
- T2DM (Type 2 Diabetes Mellitus)SGLT2-InhibitorsMetformin
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Shinshu University
- Target Recruit Count
- 120
- Registration Number
- NCT05469659
- Locations
- 🇯🇵
Shinshu University, Matsumoto, Nagano, Japan
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05327127
- Locations
- 🇺🇸
Centricity Research, Columbus, Georgia, United States
🇺🇸Birmingham Digestive Health Research, Inc., Birmingham, Alabama, United States
🇺🇸Adobe Clinical Research, LLC, Tucson, Arizona, United States
Pharmacokinetic Drug-Drug Interaction Study Between K-877 and CSG452 in Healthy Adult Volunteers
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04237597
- Locations
- 🇺🇸
PPD Development. LP, Austin, Texas, United States
SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Kanazawa University
- Target Recruit Count
- 40
- Registration Number
- NCT02649465
- Locations
- 🇯🇵
Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan
Tofogliflozin GLP-1 Analogue Combination Trial
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Kowa Company, Ltd.
- Target Recruit Count
- 65
- Registration Number
- NCT02537834
TOFO Insulin Combination Trial
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 211
- Registration Number
- NCT02201004
- Locations
- 🇯🇵
Investigational Site Number 392-004, Koga-shi, Japan
🇯🇵Investigational Site Number 392-016, Sendai-shi, Japan
🇯🇵Investigational Site Number 392-007, Atsugi-shi, Japan
A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes
- First Posted Date
- 2010-01-07
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 22
- Registration Number
- NCT01044017
A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 36
- Registration Number
- NCT00933972
A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 394
- Registration Number
- NCT00800176
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.